Please login to the form below

Not currently logged in
Email:
Password:

Dr Steven Gillis joins Shire’s board of directors

He will sit on the pharma firm's science and technology and its remuneration committee

Steven Gillis - ShireShire has appointed managing director of Arch Venture Partners Dr Steven Gillis to its board of directors.

Dr Gillis will join the Ireland-based pharma firm on October 1, becoming a member of its science and technology committee as well as its remuneration committee.

Commenting on his appointment, he said: “Shire has a clear and ambitious patient-focused vision for the future and I look forward to the opportunity to help them achieve it.”

A trained immunologist, Dr Gillis has experience in the life sciences industry through his work at Arch, which provides venture capital to firms working on new life sciences technologies.

Prior to this role, Dr Gillis was a founder and director of Corixa Corporation, which was acquired by GlaxoSmithKline in 2005 (GSK), and he was previously a founder and director of Immunex Corporation.

He currently holds a number of other roles, including as a non-executive director of New Zealand-based biotech Genesis Research and Development Corporation.

10th September 2012

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...